Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma

AIDS

Volumn 13, Issue 15, 1999, Pages 2105-2111

  Bower, Mark ^a   Fox, Paul ^a   Fife, Kate ^a   Gill, Jas ^a   Nelson, Mark ^a   Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Highly active antiretroviral therapy; Kaposi's sarcoma

Indexed keywords

ALITRETINOIN; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VINBLASTINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; FOLLOW UP; HUMAN; INFECTION CONTROL; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TIME; TOPICAL DRUG ADMINISTRATION; TREATMENT FAILURE; VIRUS LOAD; VIRUS TITRATION;

ADULT; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SARCOMA, KAPOSI; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 0032750443     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910220-00014     Document Type: Article

References (41)

1. Centre for Disease Control. First 500 000 AIDS cases - United States 1995. MMWR 1995, 44:849-853.
2. Jones J, Hanson DL, Dworkin MS, Ward JW, Jaffe HW. Effect of antiretroviral and other antiviral therapies on the incidence of Kaposi's sarcoma and trends in Kaposi's sarcoma. Proc 12th World AIDS conference. Geneva 1998: 134.
3. Kinlen LJ, Shell AG, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979, 2:1461-1466.
4. Penn I. Kaposi's sarcoma in immunosuppressed patients. J Clin Lab Immunol 1983, 12:1-10.
5. Starzl TE, Naleshik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1:583-587.
6. Langford A, Ruf B, Kunze R, Pohle HD, Reichart P. Regression of oral Kaposi's sarcoma in a case of AIDS on zidovudine (AZT). Br J Dermatol 1989, 120:709-713.
7. Krown SE, Gold JW, Niedzwiecki D, et al. Interferon-α with zidovudine: safety, tolerance and clinical and virological effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990, 112:812-821.
8. Fischl MA, Finkelstein DM, He W, et al. A phase II study of recombinent human interferon-α2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS clinical trials group. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:379-384.
9. Conant MA, Opp KM, Poretz D, Mills RC. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir [letter]. AIDS 1997, 11:1300-1301.
10. Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor [letter]. AIDS 1997, 11:261-262.
11. Burdick AE, Carmichael C, Rady PL, Tyrink SK, Badiavas E. Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus-8 DNA in a patient with AIDS after protease inhibitor therapy. J Am Acad Dermatol 1997, 37:648-649.
12. Volm MD, J. W. Patients with advanced AIDS-related Kaposi's sarcoma no longer require systemic therapy after introduction of effective antiretroviral therapy. Proc ASCO 1997, 16:47a
13. Aboulafia DM. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc 1998, 73:439-443.
14. Jung C, Bogner JR, Goebel F. Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy. Eur J Med Res 1998, 3:439-442.
15. Diz Dios P, Ocampo Hermida A, Miralles Alvarez C, Vazquez Garcia E, Martinez Vazquez C. Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy. Oral Oncol 1998, 34:236-238.
16. Krischer J, Rutschmann O, Hirschel B, Vollenweider-Roten S, Saurat JH, Pechere M. Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J Am Acad Dermatol 1998, 38:594-598.
17. Tavio M, Nasti C, Spina M, Errante D, Vaccher E, Tirelli UT. Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma. Ann Oncol 1998, 9:923.
18. Lebbé C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998, 12:F45-F49.
19. Wit FW, Sol CJ, Renwick N, et al. Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy [letter]. AIDS 1998, 12:218-219.
20. Martinelli C, Zazzi M, Ambu S, Bartolozzi D, Corsi P, Leoncini F. Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir [letter]. AIDS 1998, 12:1717-1719.
21. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J. Clin Oncol 1989, 7:1201-1207.
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
23. Peto R, Pike M, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient II: analysis and examples. Br J Cancer 1977, 35:1-39.
24. Krown SE, Testa MA, Huang J, for the AIDS Clinical Trials Group Oncology Committee. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group Staging Classification. J Clin Oncol 1997, 15:3085-3092.
25. Bodsworth N. Topical 9-cis-retinoic acid (Panretin) gel as treatment of cutaneous AIDS-related Kaposi's sarcoma: interim results of an international placebo-controlled trial (ALRT 1057-503). Proc 12th World AIDS Conference. Geneva 1998:317.
26. Bower M, Fife K, Landau D, Gracie F, Phillips RH, Gazzard BG. Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma. Int J STD AIDS 1997, 8:518-521.
27. Fife K, Howard MR, Gracie F, Phillips RH, Bower M. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998, 9:751-755.
28. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990, 335:123-128.
29. Buchbinder SP, Vittinghoff E, Colfax G, Holmberg S. Declines in AIDS incidence associated with highly active anti-retroviral therapy (HAART) are not reflected in KS and lymphoma incidence. Proc 2nd National AIDS malignancy Conference. Bethesda, Maryland. 1998:S7.
30. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266:1865-1869.
31. Fife K, Bower M. Recent insights into the pathogenesis of Kaposi's sarcoma. Br J Cancer 1996, 73:1317-1322.
32. Boshoff C, Schulz TF, Kennedy MM, et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1995, 1:1274-1278.
33. Whitby D, Howard MR, Tenant Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995, 346:799-802.
34. Cao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996, 2:925-928.
35. Miller G, Rigsby MO, Heston L, et al. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med 1996, 334:1292-1297.
36. Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 1996, 2:918-924.
37. Lennette EL, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996, 348:858-861.
38. Morfeldt L, Torssander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994, 26:749-752.
39. Mocroft A, Youle M, Gazzard BG, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996, 10:1101-1105.
40. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. J Clin Invest 1997, 99:2082-2086.
41. Autran B, Carcelain G, Li T, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.